5
Views
0
CrossRef citations to date
0
Altmetric
Cardiovascular Agents (Including Blood Products)

Antithrombotic, Antihypertensive/PAF-Antagonist: Novel Pyridinium Nitrate Derivaties as PAF Antagonists

Pages 765-766 | Published online: 02 Mar 2011
 

Summary

Novelty: 3-Bromo-5-rN-phenyl-N-[2-[[2-(1,2,3,4-tetrahydro-2-isoquinolylcarbonyloxy) ethyl]-carbamoyl]ethyl]carbamoyl]-1-propylpyridinium nitrate, which exhibits excellent PAF antagonism, is disclosed. It is useful in the treatment of circulatory diseases, thrombosis, cerebral apoplexy, myocardial infarction, diseases related to allergic inflammation etc.

Biology: The inhibitory action on PAF-induced rabbit platelet aggregation is assessed. Concentrations of 3 × 10−6 M and 3 × 10−7 M gives 100% inhibition and 3 × 10−8 M gives 71% inhibition. The inhibition of PAF-induced hypotension in rats is described. Inhibition is expressed as the ratio of the PAF-induced decrease in blood pressure before treatment with the test substance to the decrease after treatment. This ratio is then expressed as a percentage. A dose of 0.01 mg/kg iv of the test substance gives 93% inhibition after five minutes which falls to 24% after an eight hour period. A dose of 1 mg/kg po gave 69% inhibition after one hour and this falls to 69% after eight hours. A number of other tests are described.

Chemistry: 3-Bromo-5-[N-phenyl-N-[2-[[2-(1,2,3,4-tetrahydro-2-isoquinolylcarbonyl oxy)ethyl]-carbamoyl]ethyl]carbamoyl]-1-propylpyridinium nitrate is specifically claimed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.